Marcin Mycko

Prof. Marcin Mycko

orcid
avatar
Co-authors
avatar
Following
avatar
Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
RRR. H.S.R. Roxburgh
R. H.S.R. Roxburgh
SSS. R. Seaman
S. R. Seaman
TMT. Masterman
T. Masterman
AHA. E. Hensiek
A. E. Hensiek
SSS. J. Sawcer
S. J. Sawcer
DCD.A.S. Compston
D.A.S. Compston
Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.
18 April 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MMMarcin Mycko
Marcin Mycko
MCMaria Cichalewska
Maria Cichalewska
AMAgnieszka Machlanska
Agnieszka Machlanska
HCHanna Cwiklinska
Hanna Cwiklinska
MMMagdalena Mariasiewicz
Magdalena Mariasiewicz
KSKrzysztof W. Selmaj
Krzysztof W. Selmaj
MicroRNAs (miRNAs) are an emerging group of short, noncoding RNAs that play an important role in regulating expression of classical genes. Thus far little is known about their role in autoimmune demyelination. In this study, we analyzed changes in the miRNA profile in CD4+T cells that occurred during the recognition of the myelin autoantigen, MOG35–55. We found that, both in vivo and in vitro, myelin antigen stimulation resulted in significant up-regulation of miR-301a, miR-21, and miR-155. Furthermore, these three miRNAs were overexpressed in T cells infiltrating the CNS in animals with experimental autoimmune encephalomyelitis. Use of specific miRNA antagonists, antagomirs, revealed that miR-301a contributed to the development of the T-helper type 17 subset via targeting the IL-6/23–STAT3 pathway. This contribution appeared to be mediated by the miR-301a effect on the expression of the PIAS3, a potent inhibitor of the STAT3 pathway. Manipulation of miR-301a levels or PIAS3 expression in myelin-specific CD4+T cells led to significant changes in the severity of experimental autoimmune encephalomyelitis. Thus, we have identified a role of miR-301a in regulating the function of myelin-reactive T-helper type 17 cells, supporting a role for miR-301a and PIAS3 as candidates for therapeutic targets for controlling of autoimmune demyelination.
23 May 2017 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
ISIgor Selmaj
Igor Selmaj
MCMaria Cichalewska
Maria Cichalewska
MNMagdalena Namiecinska
Magdalena Namiecinska
GGGrazyna Galazka
Grazyna Galazka
WHWojciech Horzelski
Wojciech Horzelski
MMMarcin Mycko
Marcin Mycko
1 May 2003 in Brain
Verified
Journal Article
Open access
PDF file
MMMarcin Mycko
Marcin Mycko
RPRuben Papoian
Ruben Papoian
UBUrsula Boschert
Ursula Boschert
CRCedric S. Raine
Cedric S. Raine
KSKrzysztof W. Selmaj
Krzysztof W. Selmaj
CDNA microarray analysis of the regions of pathologically proven different activity of multiple sclerosis lesions was performed. Major differences in gene expression (DGE) occurred between the lesion margin and lesion centre in active lesions studied (57 and 69 genes differentially expressed, respectively), whereas the margins and centres of silent lesions showed markedly reduced heterogeneity (only 11 and two genes differentially expressed, respectively). To compare differences between chronic active and silent lesions, we performed DGE comparison of the pooled data from both types of lesions. The major DGE occurred at the lesion margin, 156 (26; 5%), the greater number representing upregulated genes at the margin of active lesions (15%). Fourteen genes were found to be significantly upregulated in marginal versus central zones in active lesions examined. These genes comprised predominantly inflammation/immune‐related factors. We also performed DGE analysis of pooled genes upregulated at the margin of active lesions and found that among the 50 genes showing differences, nine out of 14 were identified in the previous analysis of overlapping differentially expressed genes. Thus this microarray analysis has identified a novel set of genes associated with lesion activity in multiple sclerosis, many of them not previously linked with the disease.
1 May 2017 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
ISIgor Selmaj
Igor Selmaj
MMMarcin Mycko
Marcin Mycko
CRCedric S. Raine
Cedric S. Raine
KSKrzysztof W. Selmaj
Krzysztof W. Selmaj
1 March 2016 in Mucosal Immunology
Verified
Journal Article
Closed access
NLNatalia Lewkowicz
Natalia Lewkowicz
MMMarcin Mycko
Marcin Mycko
PPPatrycja Przygodzka
Patrycja Przygodzka
HCHanna Cwiklinska
Hanna Cwiklinska
MCM Cichalewska
M Cichalewska
PLP Lewkowicz
P Lewkowicz